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ABSTRACT
Chondrosarcoma (CS) is a rare tumour type and the most common primary malignant bone cancer in 
adults. The prognosis, currently based on tumour grade, imaging and anatomical location, is not reliable 
and more objective biomarkers are required. We aimed to determine whether the level of circulating 
tumour DNA (ctDNA) in the blood of CS patients could be used to predict outcome. In this multi-
institutional study, we recruited 145 patients with cartilaginous tumours, of which 41 were excluded. 
ctDNA levels were assessed in 83 of the remaining 104 patients, whose tumours harboured a hotspot 
mutation in IDH1/2 or GNAS. ctDNA was detected pre-operatively in 31/83 (37%) and in 12/31 (39%) 
patients post-operatively. We found that detection of ctDNA was more accurate than pathology for 
identification of high-grade tumours and was associated with a poor prognosis; ctDNA was never 
associated with CS grade 1/atypical cartilaginous tumours (ACT), which are neoplasms sited in the small 
bones of the hands and feet or in tumours measuring less than 80 mm. Although the results are promising, 
they are based on a small number of patients and therefore introduction of this blood test into clinical 
practice as a complementary assay to current standard-of-care protocols would allow the assay to be 
assessed more stringently and developed for a more personalised approach for the treatment of patients 
with CS. 
1. INTRODUCTION
Central conventional chondrosarcoma (CS) and dedifferentiated chondrosarcoma (DDCS) 
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disease is largely determined by assessment of tumour grade and staging[1], [2] in the context of the 
anatomical site, and imaging of the primary tumour[2]. However, the inter-observer variation in grading 
cartilaginous tumours by pathologists and radiologists demonstrates that these criteria are not reliable[3], 
[4]. Individual patient management would benefit from a more robust biomarker to predict relapse risk and 
survival, and which could also be used for assessing response to treatment in clinical trials. 
Well-differentiated central cartilaginous tumours include enchondroma, atypical cartilaginous 
tumour (ACT) and CS Grade (G) 1. ACT and CS G1 account for approximately 50% of central 
cartilaginous tumours (the incidence of enchondromas is unknown); they exhibit similar histological 
features and are distinguished on the basis of anatomical site, which determines clinical outcome and 
therefore management[2]. Well differentiated cartilaginous tumours occurring in the small tubular bones of 
the hands and feet and long bones have an excellent clinical outcome following curettage and are referred 
to as ACT[2]. Indeed, patients with CS G2 and G3 in the extremities rarely die of their disease because the 
risk of metastases is negligible[2], [5][2]. In contrast, well differentiated tumours presenting in the axial 
skeleton, pelvis, scapula, ribs, and base of skull are referred to as CS G1 because of the high incidence of 
local recurrence at these sites even after attempted curative surgery[2]. A risk of transformation to a higher 
grade comes with incomplete excision[6]. 
 CS G2 represents approximately 40% of central CS[7]. The majority of those affected will have 
major surgery involving en bloc excision, and when sited in the long bones, endoprosthetic reconstruction: 
the five-year survival ranges from approximately 70 to 99% [2], [7]–[10]. By contrast, CS G3 - 
representing about 10% of all central CS - receive the same treatment as G2 disease but have a worse 
prognosis with a five year survival ranging from 30%-77%[7], [10]. Deaths continue to occur up to and 
beyond 10 years[7], [9]. Around 10% of all conventional chondrosarcoma become dedifferentiated, which 
is associated with  a poor prognosis (7-24% 5-year survival[11]). Variable clinical outcomes in tumours of 
the same grade are likely to be accounted for, at least in part, by the inter-observer variability between 
cellular pathologists but also by differences in follow-up, anatomical site and clinical management[7], [8]. 
In 2011, we reported that approximately 60% of central conventional and dedifferentiated CS 
harbour either an IDH1 or an IDH2 hotspot mutation[12], [13]. These mutations do not occur in peripheral 
chondrosarcomas, which are considerably less common than their central counterpart[2]. As these genetic 
events occur early in the evolution of the disease[12], [14]–[16], and appear to be retained if the tumour 
transforms into higher grade disease[14], we considered that they could be exploited as biomarkers for 
clinical outcome. Other recurrent genetic events in CS, including COL21A, CDKN2A and TP53, do not 
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this project, hTERT canonical mutations have been identified as a marker of high grade disease[18], [19], 
and consequently was not a focus in this study.
Circulating tumour DNA (ctDNA) has shown promise as a minimally invasive tumour biomarker for many 
cancers in which it has predicted outcome and has been applied as a serial monitoring tool to detect early 
relapse[20]–[22]. Previously, we reported results from a small cohort of patients with central cartilaginous 
tumours (n=29 CS) and showed that IDH1- and IDH2-mutant molecules (ctDNA) could be detected in 
plasma from all patients with CS G3 and dedifferentiated CS, in approximately 50% of those with G2 
disease and never in patients diagnosed with well differentiated cartilaginous tumours[23]. Here, we report 
a multi-institutional follow-up study in which we employed a standardised protocol for screening IDH1- 
and IDH2-mutant molecules in circulating free DNA (cfDNA) from patients with CS. Furthermore, as 
central CS may occur in a small proportion of patients with fibrous dysplasia, a benign fibro-osseous 
tumour caused by pathognomonic GNAS hotspot mutations[24], we assessed if detection of mutant GNAS 
molecules in plasma could also be employed in a similar manner to that of IDH1/2-mutated ctDNA. We 
provide further evidence that screening for the presence of IDH1- and IDH2-mutant molecules in plasma 
from patients with central cartilaginous tumours leads to a more accurate grade and prognosis, when 
interpreted in the context of imaging and anatomical site, than currently provided. 
2. Materials and Methods
The project was registered as a NIHR portfolio study (CPMS ID - 35720 ‘Does circulating DNA predict 
the grade and disease burden of chondrosarcoma? A nationwide collaboration Study ctDNA and 
cartilaginous tumours)’ approved by the Bloomsbury Research Ethics Committee: REC 17/LO/1423: IRAS 
project ID: 228173. Ethical approval was also obtained from the Research Tissue Bank UCL/UCLH 
Biobank ‘Studying Health and Disease from the Health Research’; National Research Ethics Committee 
reference 15/YH/0311. IRAS project ID: 183090. Written informed consents were obtained from the 
patients and the study was conducted in accordance with the Declaration of Helsinki.
2.1. Study design
The aim was to enroll a minimum of 100 patients diagnosed with a central conventional or dedifferentiated 
cartilaginous tumours and 30 patients with enchondromas over 24 months from four bone tumour units in 
England and to follow all patients for a minimum of 12 months. The aims of the project were to determine 
if (i) ctDNA in conjunction with imaging could diagnose chondrosarcoma without biopsy, (ii) pre-operative 
ctDNA levels indicated poorer prognosis, (iii) if ctDNA detection after surgery indicated residual disease, 
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Children and patients with peripheral cartilaginous tumours were excluded. The age of the patient at the 
time of diagnosis of the cartilaginous tumour was defined as the date on which the tumour of interest was 
diagnosed, not the date on which the diagnosis of a syndrome, such as Olliers disease or fibrous dysplasia 
was made (Details of study protocol in Supplementary data).
The study was opened and the first patient was enrolled in October 2017; the study was closed at the end of 
December 2020, which included a six month extension due to the Covid pandemic. However, 23 patients 
diagnosed prior to the start date for whom plasma samples had been biobanked were enrolled in the study 
(ethics ref: 15/YH/0311) (Supplementary Table 1). Blood samples of 20ml were to be taken prior to 
surgical treatment, at the first follow up appointment which occurred at approximately 6 weeks later, at 
regular intervals thereafter to coincide with outpatient appointments or if they were admitted to hospital 
between scheduled appointments (described in the protocol, see Supplementary data). Interim blood 
samples could also be taken by a patient’s General Practitioner; all samples were processed in the 
laboratory at the Royal National Orthopaedic Hospital (RNOH). 
Tumour samples were processed and reported in the four diagnostic pathology laboratories according to 
their standard operating procedures. The formalin-fixed paraffin-embedded (FFPE) tumour biopsy and a 
representative block of the surgical specimen were sent to RNOH for review and DNA extraction. Grading 
was determined on the biopsy and reassessed on the surgical specimen. 
DNA was extracted from 4-10 µm sections of FFPE tumour tissue (some were microdissected to avoid 
dilution with DNA from normal cells), using the QIAamp® DNA FFPE Tissue kit (Qiagen, Hilden, 
Germany) as per the manufacturer’s instructions. 50 µL of elution buffer was passed through the column 
twice to increase the yield. For frozen sections, DNA was extracted from 20-60 µm sections using the 
QIAamp® DNA Mini kit (Qiagen, Hilden, Germany) as per the manufacturers’ instructions. 200 µL of 
elution buffer was passed through the column twice to increase the yield. DNA concentration was 
evaluated using a Qubit™ dsDNA HS Assay kit (ThermoFisher Scientific, MA, USA) and a NanoDrop™ 
One Spectrophotometer (ThermoFisher Scientific) and stored at -20°C. 
All samples were screened first for R132 IDH1-mutations, and if not identified the samples were tested for 
R172 IDH2 mutant molecules; R201C GNAS mutant molecules were sought in material from three patients 
whose CS arose on the background of fibrous dysplasia (Mazabraud syndrome)[25]. As the IDH1 and 
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deamination of cytosine in FFPE DNA[23], the DNA from FFPE samples was treated with uracil DNA 
glycosylase (Cat no. M0280, New England BioLabs, USA) as per the manufacturers protocol prior to 
running their respective assays. 
2.2. Processing of blood samples
Blood was received either in EDTA or PAX gene blood tubes (Qiagen, Hilden, Germany). Samples in 
EDTA tubes were processed within two hours of being drawn from the patient. Blood in PAX gene tubes 
were maintained at room temperature and processed within 10 days of being taken. The blood was 
centrifuged (VWR, PA, USA) at 1600g for 10 minutes at 4°C, after which the plasma was decanted into 
DNA LoBind tubes (Eppendorf, Stevenage, UK). The tubes were then spun again (ThermoFisher, MA, 
USA) at 1880g for 10 mins at 4°C to remove remaining blood cells. 
2.3. cfDNA extraction from plasma
Circulating free DNA (cfDNA) was extracted from 3 mL plasma per time point, using the QIAamp® 
Circulating Nucleic Acid kit (Qiagen) according to the manufacturer’s protocol. 55 µL of elution buffer 
was passed through the column twice to increase the yield. Once extracted, purified cfDNA was eluted and 
stored at -20°C prior to use.
2.4. Droplet digital PCR (ddPCR) assays and analysis
cfDNA and tumour DNA was analysed on the QX200 Droplet Digital PCR System (Bio-Rad, CA, USA). 
20 μL reactions consisted of up to 8.8 μL DNA, 10 μL 0.02x Supermix for Probes (no dUTP; Cat.No 186-
3023, Bio-Rad, USA), 18 mM forward and reverse primers, 0.05 mM probe, and nuclease-free water. 
Droplets were generated on the QX100 Droplet Generator (Bio-Rad), which then underwent 40 cycles of 
PCR (T100 Thermocycler, BioRad; 95⁰C for 10 min, 44 cycles of 94⁰C for 30 sec, X⁰C for 1 min (X is 
assay specific, Supplementary Table 2) prior to reading on a QX200 droplet reader (Bio-Rad). Droplets 
were read with either the FAM/VIC or FAM/HEX channels setting provided by the QuantaSoft 1.7.4 
software package (Bio-Rad). Droplets were inspected visually and called as ‘mutant only’, ‘WT only’, 
‘double-positive’ or ‘template negative’. The presence of a detectable mutation in each tumour was verified 
in a multiplex experiment prior to the running of plasma samples, as previously reported[23]. A positive 
control, WT DNA and no-template control were included in each run. The positive control was a patient’s 
sample with a mutation verified via whole genome analysis (100,000 Genomes Projec[26], [27]), and the 
WT sample was a commercially available pooled sample of human placental DNA (BioLine, London, UK). 
The inclusion of the WT and no template control (H2O) in each assay run was used as a measure of 
background error rate. The plots were visualised in all cases. Each cfDNA sample was run in duplicate (8.8 
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plasma samples were deemed to be mutant-positive if they had a minimum of 2 “mutant only” droplets 
with over 10,000 WT droplets also called. Samples with just a single mutant droplet were classified as 
equivocal and retested (2 mL plasma). For the plasma samples mutant droplets were reported in terms of 
mutant copies per mL of blood plasma analysed. Blood samples were classified as containing circulating 
tumour DNA (ctDNA) if a minimum of two mutant only droplets were detected. Supplementary Table 3 
summarises all ddPCR results for the ctDNA positive cases.When available, post-operative plasma sample 
were tested for ctDNA from those patients that were pre-operative negative for ctDNA, but who suffered a 
clinical relapse. In all instances these plasma samples remained ctDNA negative. IDH1 (n=20) and IDH2 
mutations (n=4) detected by ddPCR in this study were confirmed in the same tumours which had 
undergone whole genome sequencing as part of the 100,000 Genomes Project[27] (Supplementary Table 
1).
Specifically, both the mutant and wildtype probes, for the IDH and GNAS assays, were multiplexed in the 
same assay and this approach was used as a control to monitor the amount of DNA input into the assay. In 
the pilot study[23], we recognised that little DNA resulted in a weak or low level of our IDH wildtype 
probe, whereas too much DNA changed the shape of the plot resulting in the assay being classified as ‘fail’. 
Therefore, the amount of plasma extracted (~3mL) was chosen so that >95% of the samples would fall 
within the testable range. Any samples which failed were retested, however, only one case (ID99) required 
a lower DNA volume input in the pre-op sample and notably this occurred in a patient who had suffered a 
pathological fracture which may have explained the finding. 
Findings in our current study confirm our previous results in terms of interpreting ctDNA in patients with 
multiple enchondromas.  This is illustrated by the following cases: ID140: a cartilage tumour in the radius 
from a patient with Ollier disease was diagnosed as an enchondroma following a needle biopsy and a 
decision was made not to treat. However, ctDNA was detected 60 days later prior to curettage of an 
enchondroma in the phalanx. A post-curettage plasma was not available, but the disease in the affected arm 
or at other sites has not progressed (follow-up>4 years). ID126: ctDNA was not detected prior to the 
resection of the G1 chondrosarcoma of the scapula but post-operatively IDH1-mutant molecules were 
detected. Neither this tumour nor other lesions have required treatment in the last 20 years since surgery.
Of the other 12 cases arising in Ollier disease or Maffucci syndrome, the tumours of interest were 
classified enchondromas (n=2), G1 (n=4), G2 (n=5), G3 (n=1). ctDNA was detected pre-operatively in 
three cases, all G2.
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Imaging was reviewed by specialist musculoskeletal radiologists from the four units, each responsible for 
their own cases with no central or consensus review. Tumours were graded  according to radiological 
features which covered pathology categories low grade/ well-differentiated (enchondroma/ ACT/ CS G1), 
high grade was represented by CS G2/3 without distinction being made between G2 and G3 tumours; 
dedifferentiated (G4) CS, with distinction between low- and high grade appendicular lesions according to 
previously published criteria[28]. The tumours were measured in all three orthogonal planes using the 
standard PACS electronic callipers and the maximum dimension recorded. The radiologists were not aware 
of the histological grade. The date of imaging detection of recurrence, either local (based on MRI of the 
surgical site) or distant (based on plain film or CT imaging of the chest) was noted for each case.
2.6. Pathology review
The histology was classified using the WHO criteria[2] (2020) after which enchondromas, ACT and CS G1 
were referred to as well differentiated cartilaginous tumours. All cases were reviewed independently by at 
least two pathologists (AMF, RT) blinded to the radiology and the original pathology reports. Where there 
was a disagreement the cases were reviewed together and a consensus was reached (Supplementary Table 
1).
2.7. Statistical analysis
Statistical analysis was performed using the R statistical software[29]. Summary statistics were performed. 
Categorical variables were compared using the Fisher’s exact test. A p-value <5% was deemed statistically 
significant. Survival analysis was performed using the Kaplan-Meier estimator with death as the end point. 
Overall survival was defined as time from diagnosis to disease-related mortality or censured at the 
timepoint for the last follow-up. Survival analysis utilised a standard Cox proportional hazard model, and 
multivariate testing was performed using ‘coxphf’ R package[30]. 
3. RESULTS
3.1. Patient cohort and samples
145 patients were recruited to the study; 41 (28%) patients were excluded for a variety of reasons 
including three patients choosing to withdraw, diagnosis of a peripheral chondrosarcoma, absence of tissue 
submitted or inadequate DNA quality or quantity from plasma or histological material (Supplementary 
Table 1). Mutational analysis was performed on the remaining samples from the 104 participants (72%) 
whose age at presentation ranged from 17-86 years (median age 53 years; 49 male, (47%), and 55 female 
(53%)). 21 patients (20%) were then excluded from further analysis as their tumours did not harbour a 
hotspot mutation of interest. The median follow up of the remaining 83 patients (80%), included in the 
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41 male (49%), 42 female (51%)). Figure 1 provides an overview of the study, with a breakdown of tumour 
grade in Supplementary Table 1. 
3.2.Radiology and pathology correlation
There was disagreement between the grading of pathology biopsies and radiology in 24 cases (17%, 
121/145 recruited patients) (Supplementary Table 1 and 4). However, it is noteworthy that in 11 of these 24 
cases the radiologists reported high grade disease (10 dedifferentiated CS and one Grade 2 CS) which were 
reported by patholgists as well differentiated tumours. These discrepancies highlight the problem of tumour 
heterogeneity and non-representative sampling on biopsy and underscores the need for multidisciplinary 
meetings.
Disagreement between pathologists was infrequent (5%, n=7) and was mainly in the differentiation of 
enchondromas from ACTs, and in tumours sited in the bones of the extremities and therefore had little 
clinical impact (Supplementary Table 1). 
3.3. IDH1 and IDH2 hotspot mutations detected in 80% of tumours
Of the 104 tumours studied, 14 patients had multiple enchondromas (13 Ollier disease and one 
Maffucci Syndrome), and three arose in patients with fibrous dysplasia (ID3, 24 and 38). A hotspot 
(recurrent) single nucleotide variant (SNV) of interest was detected in 83/104 (80%). 70 of the mutations 
were IDH1 and 10 were IDH2, excluding one IDH2 case with a pArg172lle mutation identified on whole 
genome sequencing; the IDH1 and IDH2 mutations were mutually exclusive. The remaining three patients 
harboured the R201 GNAS mutation characteristic of fibrous dysplasia. One of these tumours (ID3) also 
harboured the rare IDH2 pArg172lle mutation which our ddPCR assay was not designed to detect: the other 
two tumours (ID24, ID38) were WT for IDH1 and IDH2 mutations. 21/104 (20%) tumours were wildtype 
(WT) for hotspot IDH1/2 mutations. Table 1 and 2 provide details of tumour grade and IDH1/IDH2/GNAS 
mutation status. 
3.4. Detection of pre-operative ctDNA correlates with tumour grade 
ctDNA was detected in pre-operative plasma samples of 31/83 (37%) patients whose tumour harboured an 
IDH1 or an IDH2 mutation. The absence of ctDNA pre-operatively correlated strongly with well-
differentiated tumours (p < 0.001, Fisher’s exact test), whereas its presence was strongly associated with 
both G3 and dedifferentiated CS (p < 0.001, Table 3). The association of G2 disease with detection of 
ctDNA was not statistically significant. 
ctDNA was detected in only one of 37 subjects with a well-differentiated tumour. This patient had 
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dedifferentiated CS, and 3 of 4 cases with G3 CS diagnosed on histology. The positive association of high 
grade CS with ctDNA is strengthened by the detection of ctDNA in 6/7 patients diagnosed with well-
differentiated disease on biopsy but where the diagnosis was amended to high grade disease in the resected 
specimen (ID10, 38, 40, 54, 58, 141) (Supplementary Table 4).  Notably, these tumours were recognised as 
high grade disease by the radiologists uninformed of the ctDNA results. 
3.5. ctDNA is associated with tumour volume 
ctDNA was not detected post-operatively in 2/15 patients (ID27, ID132) with metastases. However, in 
both cases lung metastases presented after wide excision of the primary tumour; they were single lesions 
and both measured less than 40mm.  
ctDNA was detected pre-operatively in 13/14 patients with dedifferentiated CS. The exception was 
patient ID99, who presented originally with a pathological fracture of the proximal femur at the site of a G2 
tumour and was treated with resection and endoprosthetic reconstruction: ctDNA was not available before 
this first surgical procedure. ctDNA was also not detected in plasma taken at the time of the local 
recurrence 242 days following the first surgery. The excised recurrent tumour was 60 mm in maximum 
dimension and included  a dedifferentiated component, measuring 30mm. 
Analysis of the minimum tumour size that was associated with metastasis in the 83 cases studied was 
80 mm. Furthermore, we identified that detection of ctDNA pre-operatively was related to larger tumour 
size (p<0.001, Figure 2A, Table 3).
3.6. ctDNA detection and multiple enchondromas: interpret with caution
We have previously reported that detection of ctDNA can occur post-treatment of well 
differentiated tumours in the setting of multiple enchondromas, albeit in a small number of cases[23]. The 
three patients in question in the previous publication have not relapsed subsequently suggesting that 
detection of ctDNA should be interpreted with caution in this clinical setting. Findings in our current study 
confirm our previous results, as illustrated by the ID140 and ID126 (Supplementary data). Of the other 12 
cases arising in Ollier disease or Maffucci syndrome, the tumours of interest were classified as two 
enchondroma (n=2), four G1 (n=4), five G2 (n=5), one G3 (n=1). ctDNA was detected pre-operatively in 
three cases, all G2.
3.7. Failure to detect ctDNA prior to surgery correlates with a good prognosis and anatomical site
Pre-operative ctDNA was not detected in 51/81 (63%) patients, and notably ctDNA was never 
detected post-operatively if not detected pre-operatively (plasma available in 41/51 of this group). None of 
these 51 patients developed systemic disease; tumours from 16 of these patients occurred in the bones of 
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locally. Three other tumours recurred including: ID81 - G2 femoral CS in the setting of Ollier disease in 
which en bloc excision with clear margins could not be achieved because of the extent of the lesion; ID70 - 
ACT of the distal femur which recurred locally twice following curettage, after which the tumour was 
resected en bloc:  the patient has no evidence of relapse after 728 days. The final case (ID99) is described 
in section 3.4. 
Long-term follow-up is required to determine the predictive value of the absence of ctDNA 
detection pre-operatively for tumours at anatomical sites other than the bones in the hands and feet as there 
is good evidence that there is negligible risk of metastatic disease when occurring at these sites[2], [15].
3.8. Detection of ctDNA correlates with the risk of relapse
ctDNA for IDH1/2 and GNAS mutations were detected pre-operatively in a total of 30/81 (37%) 
patients harbouring the relevant hotspot mutations in their tumours. The number of mutant molecules  in 
these patients did not reflect tumour grade or tumour size. Of the post-operative plasma samples analysed 
from 69/81 patients (85%), mutant molecules were detected in 12 (15%) patients. The detection of ctDNA 
pre- and post-operatively correlates with survival (p<0.001, Figure 2B; p<0.001, Figure 2C, respectively, 
Table 3). Furthermore, the number of molecules were significantly reduced post-operatively compared with 
pre-operative levels reflecting the tumour burden (p = 0.04). 
ctDNA was detected pre-operatively in all 11 patients in whom it was also detected post-
operatively and all suffered a relapse; seven died of their disease, six with metastases (ID, 89, 54, 38, 17, 
40, 28) and patient ID34 died of massive local disease involving the aorta. Two additional patients 
developed metastatic disease: ID103 whose lung was resected is alive without disease 9 years post 
thoracotomy. The second patient ID63 is alive with lung metastases. Two other patients (ID18 vertebra G2; 
ID112 pelvis G2) have persistent local disease following extensive surgery. The final patient (ID24 
humerus, dedifferentiated) suffered a local recurrence (120 mm maximum dimension) which was treated 
with a wide local excision and has been event-free for 514 days; no plasma has been obtained since the 
local recurrence. 
Whereas ctDNA was detected post-operatively in all patients who suffered a relapse, of those in whom 
ctDNA was only detected pre-operatively 5/14 (36%) patients relapsed (ID3 sacrum, ID69 sacrum, ID27 
femur, ID132 femur, ID91 femur). Of the remaining nine patients, five are at significant risk of relapse, 
notwithstanding the major surgery undertaken with intent to cure, because of the pelvic/sacral location. 
Another four patients (ID58, 78, 129, 42) with tumours in the long bones, two with dedifferentiated CS and 
two with G2 CS, remain disease-free but the follow-up period is less than 36 months for these patients. 
Although relapse occurs in the vast majority of cases within 24 months of the primary surgery, relapse may 
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3.9. ctDNA can detect relapse earlier than imaging 
Of the 12 patients in whom ctDNA was detected both pre- and post-operatively, relapse was 
predicted by ctDNA prior to disease being detected clinically or on imaging in four cases (33%). ID34: 142 
days ahead of imaging and 205 days ahead of the diagnosis being confirmed on histology. ID28: 150 days 
ahead of histology and imaging. ID54: 58 days ahead of imaging. ctDNA was detected in ID24 32 days 
prior to a local recurrence. In the remaining 8/12 patients, ctDNA was detected at the time of clinical 
detectable relapse (Figure 3, Supplementary Table 1). ctDNA was detected on the day on which clinical 
relapse was detected in another four patients (ID18, 40, 89, 103). In the last four patients ctDNA was 
detected following relapse had been detected on radiology but prior to surgery for their metastasis/local 
recurrence (ID17, 38, 63, 112).
4. DISCUSSION 
Histological grading and imaging of cartilaginous tumours predict clinical behaviour unreliably; clinical 
and radiological surveillance are insensitive for detection of disease recurrence and are laborious and 
inefficient, particularly in patients wth large metal implants. Therefore, the identification of more sensitive 
and accurate biomarkers would allow patients to receive a more personalised treatment plan. In this 
multicentre study, we have confirmed our previous findings[23] that digital droplet PCR mutation-specific 
IDH1/2 assays can be employed for the detection of ctDNA and we also report here for the first time that 
GNAS hotspot mutations, as with IDH1/2 mutations, can be employed as a biomarker. Specifically, we 
have shown that (i) ctDNA in conjunction with imaging allows diagnosis of chondrosarcoma without 
biopsy, (ii) that pre-operative ctDNA levels indicate a significantly less favourable prognosis compared to 
those in which ctDNA was not detected, (iii) that ctDNA detection after surgery indicates residual disease 
with the exception of patients with multiple enchondromas and (iv) that serial monitoring of ctDNA detects 
disease relapse earlier than it is detected using current surveillance protocols. Although the results are 
promising and the specificity of the assay is underscored by the failure to detect mutant molecules of 
interest in the plasma of individuals with well-differentiated tumours, and cartilaginous tumours of any 
grade in the extremities, with the exception, as previously reported[23], of patients with multiple 
enchondromas, the numbers of cases studied are small. Therefore, we would advocate for the assay to be 
introduced into clinical practice alongside existing standard of care protocols for providing diagnoses and 
prognoses. This approach would allow the test to be rigorously assessed and for confidence to be built in 
this blood-based assay.  
A considerable benefit of a blood sample, over current standard of care imaging and biopsy 
performed for the purpose of diagnosis and tumour grading, is that it overcomes the challenge of tumour 
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significant impact on clinical management[6]. With our available data, we consider that this test would be a 
valuable adjunct to current standard of care testing but it would be ill-advised at present to replace a 
diagnostic biopsy. It is also noteworthy that tumours other than cartilaginous neoplasms can harbour the 
same IDH1/2 mutations assessed in our study, including carcinomas (predominantly cholangiocarcinoma), 
acute myeloid leukaemia and brain tumours although these mutations have never been identified in other 
primary bone tumours[12], [13], [31]. These findings highlight the importance of interpreting pathology in 
the context of the relevant imaging.  
Albeit in only four patients, the ctDNA assay detected relapse earlier than currently used follow-up 
methods: this small number is potentially related to the irregularity of the plasma sampling post-operatively 
and also the relatively short duration of this study. Although most relapses occur within 24 months of the 
diagnosis of chondrosarcoma, late relapses are well described[9]. However, if the assay was found to detect 
early relapse more commonly, it could potentially be useful for clinical surveillance in conjunction with 
MRI scans for chondrosarcoma, which are usually only performed when there is clinical concern of a local 
recurrence, by which time disease may be extensive and potentially unresectable. The absence of regular 
plasma samples may also have impacted on the ability to detect minimal residual disease. However, as the 
burden of disease appears to determine if ctDNA is detected, the failure to detect ctDNA is best regarded as 
an ‘uninformative’ result whereas a positive result warrants further investigations and or close surveillance. 
Although compounded in this study by the Covid19 pandemic, we consider that taking blood samples for 
the measurement of ctDNA will remain a challenge until the practice of plasma collection is introduced as 
standard of care. 
Major limitations of this study include the relatively small number of patients recruited, 
which is largely explained by the rarity of the disease. However, this number was compounded by the 
exclusion of 41 patients, 28% of those recruited because of poor quality or inadequate DNA, in addition to 
which 20-30% of chondrosarcomas which do not harbour an IDH1/2 alteration[12]. The quality of DNA 
should not have such a negative impact on molecular testing today. The Royal College of Pathologists and 
WHO guidelines recommend decalcification of biopsies and at least some tissue from resection specimens 
in EDTA, and not in nitric or formic acid, as this allows DNA of sufficient quality to be extracted and used 
successfully for molecular tests, including droplet digital PCR[2], [32]. The benefit of optimising the 
decalcification proformas across all bone tumour sites would be substantial, as molecular assays are now 
commonly used for diagnosing not only primary bone tumours but also metastatic disease to bone. The 20-
30% of central cartilaginous tumours without an IDH1/2 mutation highlights the need for additional 
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Implementation of this assay into clinical practice is the major challenge now faced. To provide 
robust evidence that this assay improves the health care of patients, ideally with cost benefit, it will be 
necessary to build a large cohort of patients with CS and obtain plasma samples regularly with long term 
follow-up. However, to ensure high level quality control of the testing with the relevant expertise, the assay 
would be best conducted in centralised laboratories.  
The benefits of ‘liquid biopsies’ have been shown in a variety of the more common cancers such as 
breast[33], lung[21] and colorectal[20]. However, the benefits of such advances are likely to be delayed for 
patients with rare cancers because of the small numbers affected. Therefore, we argue that there is a case to 
be made to collect samples from patients with rare disease as part of routine care, so that they can be 
exploited in a timely manner for patient benefit. 
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Table 1. Central chondrosarcoma histological grade on resection specimen, genotype of tumour and 
ctDNA in 104 patients
IDH1 (n=70)















Grade 2 (n=42) 26 4 11 1
Grade 3 (n=4) 2 1 1
Dedifferentiated 
(n=16)
9 2 3 2
^two tumours WT for IDH1 and IDH2 harboured a GNAS R201C mutation
^^a tumour harbouring an IDH2 mutation (pArg172lle) not detectable by dPCR harboured a GNAS R201C 
mutation. This case is not included in the group.
Table 2. Overview of correlation of tumour grade, IDH1, IDH2, and GNAS mutant profile pre-
 and post-operatively 










Grade      
 Well-diff 35 2 27 0
 High grade 17 21 29 8
 Dediff 0 8 0 5
Genetic alteration      
 IDH1 47 23 48 10
 IDH2 5 5 7 1
 GNAS 0 3 1 2
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 <=80 mm 41 5 37 2
 >80 mm 11 26 19 11
Pre-OP: Pre-operatively. Post-OP: post-operatively. Max: maximum.
Table 3. Survival correlated with tumour grade, and detection of IDH1, IDH2 and GNAS mutations 
in plasma pre- and post-operatively
Survival (years) Univariate analysis Multivariate analysis*
 HR 95% CI P-value HR 95% CI P-value
Pre-OP ctDNA 
(n=83)       
Neg (n=52) REFERENCE      
Pos (n=31) 1.2*10^9 0-Inf <0.0001 60.2 2.4-10373.7 0.008
Post-OP ctDNA 
(69)       
Neg (n=56) REFERENCE      
Pos (n=13) 18.9 3.9-91.4 <0.0001 10.7 1.8-110.3 0.007
Grade (n=83)       
Well-diff (n=36) REFERENCE      
High grade (n=37) 5 0.6-42.9 0.14    
Dediff (n=8) 41.5
4.9-
348.5 <0.001 4.2 0.5-51.6 0.17
IDH status (n=80)       
IDH1 (n=70) REFERENCE      
IDH2 (n=10) 1.5 0.1-5.0 0.7    
Gender (n=83)       
Male (n=41) REFERENCE      
Female (n=42) 2.2 0.7-7.5 0.2    
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<55years (n=41) REFERENCE      
=>55years (n=42) 0.5 0.6-7.0 0.2    
Max tumour size       
<=80 mm REFERENCE      
>80 mm 15.3 0.1-2.0 0.01 0.9 0.2-9.4 0.9
HR: Hazard ratio.CI: confidence interval. Pre-OP: Pre-operatively. Post-OP: post-operatively. 
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Figure legends
Figure 1.  Study overview. The number of enrolled patients, and samples analysed. WT= wildtype for 
IDH1, IDH2, GNAS hotspot mutations. Supplementary Table 1 provides further details on each case.
Figure 2. Detection of ctDNA pre- and post-operatively correlates with the risk of relapse
A) ctDNA detection correlates with tumour size. B) Detection of ctDNA pre-operatively and C) post-
operatively correlates with overall survival (disease-related mortality or censorship). Survival analysis 
utilised a standard Cox proportional hazard model.
Figure 3. Schema of longitudinal ctDNA assessment showing detection prior to clinical relapse. Blue lines 
indicate time of diagnosis, grey dotted lines indicate time of surgery, orange lines depicts 
clinical/radiological relapse, black filled lines indicate the time of death, and the dotted black lines 
represent the time of the last follow-up. Two post-OP ctDNA negative patients died (ID3 and 91); ID3 died 
of other causes, while ID91 died of the disease. Poor sampling in the follow-up might explain the lack of 
detection of ctDNA in this patient post-operatively. 
Supplementary information
Supplementary Table 1- Clinical information
Supplementary Table 2 – Digital droplet PCR assays
Supplementary Table 3- ctDNA results from the 31 patients with pre-OP positive samples
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